
For people newly diagnosed with advanced melanoma, a combination of two immunotherapy drugs can double the amount of time their cancer remains progression-free, a clinical trial has found. The treatment combines two drugs known as immune checkpoint inhibitors. One, called nivolumab (Opdivo), is already standard for advanced melanoma; the other, relatlimab, is not yet approved.… read on > read on >